# Comparison of Standard vs. Accelerated Corneal Crosslinking

> **NCT03922542** · PHASE2,PHASE3 · RECRUITING · sponsor: **Price Vision Group** · enrollment: 510 (estimated)

## Conditions studied

- Keratoconus
- Ectasia Corneal

## Interventions

- **COMBINATION_PRODUCT:** riboflavin 0.1%
- **COMBINATION_PRODUCT:** Riboflavin 0.1%

## Key facts

- **NCT ID:** NCT03922542
- **Lead sponsor:** Price Vision Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-16
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 510 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03922542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03922542, "Comparison of Standard vs. Accelerated Corneal Crosslinking". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03922542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*